Company intelligence / Profile preview
Pyxis Oncology
Boston, Massachusetts, United Statesir.pyxisoncology.com ↗
- Ownership
- Public · PYXS
- Employees
- ~44
- Development stage
- Other
01
Overview
Pyxis Oncology is a clinical-stage biotech developing next-generation therapeutics for difficult-to-treat cancers. Its lead program, micvotabart pelidotin (“MICVO”, formerly PYX‑201), an ADC targeting EDB+FN in the tumor stroma, is in Phase 1 trials with a focus on recurrent/metastatic HNSCC. The second program, PYX‑106, a Siglec‑15-targeting monoclonal antibody for NSCLC and other solid tumors, is also in Phase 1. A third asset acquired from Apexigen—PYX‑107/sotigalimab—is a CD40 agonist antibody currently under portfolio review after being tested in Phase 2 for melanoma/liposarcoma. Early pipeline programs have been paused or are seeking partners due to strategic reprioritization.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateMonoclonal antibodyImmunotherapy (Immuno-oncology)
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
Pfizer (in-license of ADC)Apexigen acquisition brought sotigalimab/PYX–107 into the pipelineLeaps by Bayer led Series A financing round as strategic investor
04
Financials
- Market cap
- $246.5M
- Total revenue
- $0
- Enterprise value
- $231.3M
Beyond the preview
Go deeper on Pyxis Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pyxis Oncology.